Amgen, GSK Join To Market Novel Osteo Drug In China, India, S. Korea
This article was originally published in PharmAsia News
Executive SummaryTwo multinational drug makers plan to market a new type of treatment for osteoporosis around the globe, including China, India and South Korea. U.K.-based GlaxoSmithKline is to handle marketing duties in those countries because the drug's maker, U.S.-based Amgen, does not have a presence in them. The drug is denosumab, intended to be injected only twice a year to handle the disease. It also is expected to be a blockbuster drug. (Click here for more
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.